The HIV-1 envelope (env) glycoprotein gp12O and its biosynthetic precursor gpl6O play a critical role in the pathophysiology of HIV-1 infection and are principal target antigens for HIV-1 vaccines. The long term goal of this project is to understand the recognition of these proteins by human T cells. During the initial funding period, env-specific human CD8 + and CD4 + cytolytic T lymphocytes (CTL) clones were used to analyze the mechanisms by which the env proteins are processed for recognition by T cells. For both class I- and class II-restricted recognition, novel antigen processing pathways were identified. This proposal describes further studies of env protein processing designed to determine the precise structure of the naturally processed env peptides present on infected cells and to characterize the processing mechanisms that generate these peptides. With respect to env processing for recognition by CD8 + CTL, the proposed studies will extend recent work from this laboratory showing that the env protein is processed by a novel pathway which is localized to the endoplasmic reticulum (ER) and which does not depend on the transport proteins Tap-1 and Tap-2 previously thought to be essential for presentation of viral proteins. Naturally processed env peptides will be isolated from class I molecules of infected cells and sequenced to determine whether these peptides are generated by Tap-1/Tap-2-dependent (cytoplasmic) or Tap-1/Tap-2-independent (ER) processing reactions. The relationship between ER processing of the HIV-1 env protein and other ER proteolysis reactions will be evaluated and the hypothesis that targeting of the env protein for ER degradation can enhance processing and presentation of env epitopes will be tested. In addition, studies are proposed to determine whether this novel pathway is utilized by all viral envelope proteins. With respect to env processing for recognition by CD4 + T cells, the proposed studies will extend work form this laboratory showing that endogenously synthesized env protein is directly processed in infected cells for association with class II MHC molecules. The hypothesis that this processing reaction operates on env protein internalized from the cell surface will be tested by isolating and sequencing naturally processed env peptides from the class II molecules of infected cells and by comparing their structures with those generated by processing of exogenous env protein. Studies with env mutants will address whether env processing is inhibited by mutations that alter potential internalization signal sequences or enhanced by mutations that target env protein to lysosomes. In addition to providing basic information about antigen processing, these studies may facilitate the design of new vaccines that elicit an """"""""optimized"""""""" T cell response specific for the exact antigenic peptides expressed on infected cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37AI028108-15
Application #
6532679
Study Section
Special Emphasis Panel (NSS)
Program Officer
Plaeger, Susan F
Project Start
1998-08-15
Project End
2004-07-31
Budget Start
2002-08-01
Budget End
2004-07-31
Support Year
15
Fiscal Year
2002
Total Cost
$360,043
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Wong, S B Justin; Siliciano, Robert F (2005) Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice. J Virol 79:1701-12
Wong, S B Justin; Buck, Christopher B; Shen, Xuefei et al. (2004) An evaluation of enforced rapid proteasomal degradation as a means of enhancing vaccine-induced CTL responses. J Immunol 173:3073-83
Shen, Xuefei; Wong, S B Justin; Buck, Christopher B et al. (2002) Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes. J Immunol 169:4222-9
Buck, C B; Shen, X; Egan, M A et al. (2001) The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site. J Virol 75:181-91
Ferris, R L; Hall, C; Sipsas, N V et al. (1999) Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: dependence on TAP1/2 and mechanisms for cytosolic localization. J Immunol 162:1324-32
Tobery, T; Siliciano, R F (1999) Cutting edge: induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen. J Immunol 162:639-42
Finzi, D; Siliciano, R F (1998) Viral dynamics in HIV-1 infection. Cell 93:665-71
Ray, S C; Lubaki, N; Dhruva, B R et al. (1998) Autologous strain-specific cytolytic T lymphocyte responses directed against human immunodeficiency virus type 1 Env. AIDS Res Hum Retroviruses 14:3-13
Tobery, T W; Siliciano, R F (1997) Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med 185:909-20
Lubaki, N M; Ray, S C; Dhruva, B et al. (1997) Characterization of a polyclonal cytolytic T lymphocyte response to human immunodeficiency virus in persons without clinical progression. J Infect Dis 175:1360-7

Showing the most recent 10 out of 36 publications